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Using the homologous recombination machinery of E. coli, a 1.245-kb deletion was introduced in the E3 region of bovine
adenovirus 3 (BAV3) genomic DNA cloned in a plasmid. Transfection of the restriction enzyme-excised, linear E3-deleted
BAV3 genomic DNA into primary fetal bovine retina cells produced infectious virus (BAV3.E3d), suggesting that all the
E3-specific open reading frames are nonessential for virus replication in vitro. Using a similar approach, we constructed
replication-competent (BAV3.E3gD and BAV3.E3gDt) BAV3 recombinant expressing full-length (gD) or truncated (gDt) glyco-
protein of bovine herpes virus 1. Recombinant gD and gDt proteins expressed by BAV3.E3gD and BAV3.E3gDt, respectively,
were recognized by gD-specific monoclonal antibodies directed against conformational epitopes, suggesting that antigenicity
of recombinant gD and gDt was similar to that of the native gD expressed in bovine herpes virus 1-infected cells. Intranasal
immunization of cotton rats induced strong gD- and BAV3-specific IgA and IgG immune responses. These results suggest
that replication-competent bovine adenovirus 3-based vectors have potential for the delivery of vaccine antigens to the
mucosal surfaces of animals. © 1998 Academic Press
INTRODUCTION
Vaccination has proved to be the most effective means
of controlling respiratory and enteric viral diseases, es-
pecially when live attenuated viral vaccines have been
used. These vaccines, when administered orally or intra-
nasally, induce a strong mucosal immunity, which is
required to block the initial infection and to reduce the
development of disease caused by these viruses. This
approach has been extended by using genetically engi-
neered virus genomes (virulence gene deleted) as vec-
tors to express and deliver genes of other pathogens in
vivo (Ertl and Xiang, 1996). One such recombinant viral
vector system recently developed is based on human
adenoviruses (HAVs) (Graham and Prevec, 1992). Both
replication-defective and replication-competent HAV vec-
tors have been engineered to express various foreign
antigens (for reviews, see Grunhaus and Horwitz, 1992;
Imler, 1995). In addition to stable foreign gene expres-
sion, engineered adenoviruses have been shown to in-
duce humoral, cellular, and mucosal immune responses
(Buge et al., 1997).
We have been carrying out the molecular character-
ization of bovine adenovirus 3 (BAV3) with the aim of
developing BAV3 as a live viral vector for animal vac-
cines and human gene therapy. BAV3, a representative
of subgroup I of BAVs (Bartha, 1969), has been shown
to replicate in the respiratory tract of cattle, producing
mild or no clinical symptoms (Darbyshire et al., 1965).
Like other adenoviruses, BAV3 is a nonenveloped ico-
sahedral particle of 75-nm diameter (Niiyama et al.,
1975) containing a linear double-stranded DNA mole-
cule. Recently, the complete DNA sequence and tran-
scriptional map of BAV3 genome were reported (Baxi
et al., 1998; Lee et al., 1998; Reddy et al., 1998).
Although the size (34,446 bp) and the overall organi-
zation of the BAV3 genome appear to be similar to
those of HAVs, there are certain differences (Reddy et
al., 1998). One of the distinctive features of BAV3
genome is the relatively small (1517 bp) size of the E3
coding region (Mittal et al., 1993; Reddy et al., 1998).
Analysis of the sequence of the E3 region genome and
RNA transcripts (Idamakanti, 1998) suggests that BAV3
E3 region may code at least four proteins, one (121R)
of which shows limited homology to 14.7-kDa protein
of HAV5 (Mittal et al., 1993).
In this report, we describe an easy and efficient
method of constructing an E3-deleted recombinant BAV3.
In addition, we describe the construction of recombinant
BAV3 expressing different forms of bovine herpes virus 1
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(BHV-1) glycoprotein gD and show that intranasal immu-
nization of cotton rats leads to the induction of a gD-
specific mucosal and systemic immune response.
RESULTS
Construction of E3-deleted recombinant BAV3
Initially, it was assumed that the role of BAV3 E3 in
virus replication would be similar to the that of E3 region
of HAV (Wold and Gooding, 1991). Therefore, the E3-
based vectors were constructed by making deletions of
the E3 sequences. However, attempts to isolate an E3-
deleted BAV3 recombinant in different bovine cell lines,
including Madin–Darby bovine kidney (MDBK), were un-
successful. A partially deleted BAV3 (BAV3-Luc) recom-
binant expressing luciferase gene could only be isolated
when BAV3 E1-transformed MDBK cells were used for
transfection (Mittal et al., 1995). However, this recombi-
nant BAV3 could be propagated on normal bovine cells,
suggesting that E3 region of BAV3 was not essential for
virus replication in vitro (Mittal et al., 1995). To increase
the efficiency of isolating a BAV3 recombinant, we used
primary fetal bovine retina (PFBR) cells and a novel
procedure (Degryse, 1996) for generating BAV3 recombi-
nants. Using this method, targeted modifications of the
viral genome were introduced into a plasmid using the
highly efficient homologous recombination machinery of
Escherichia coli. The infectious virions are isolated after
transfection of the adenovirus genome, excised by PacI
digestion from the plasmid vector by restriction endonu-
clease digestion, into appropriate host cells (Chartier et
al., 1996).
Taking advantage of the homologous recombination
machinery of E. coli, we constructed a plasmid (pF-
BAV302) that contained a 1.245-kb deletion (nucleotides
26,456–27,701) and an SrfI restriction enzyme site (Fig. 1).
The PacI digested pFBAV302 DNA when transfected into
PFBR cells produced cytopathic effects in 14 days. The
virus named BAV3.E3d was plaque purified and ex-
panded in MDBK cells. The viral DNA was extracted and
analyzed by agarose gel electrophoresis after digestion
with BamHI restriction enzyme. The wild-type BAV3 had a
BamHI fragment of 3.019 kb (Fig. 2, lane b) that was
missing in the recombinant BAV3.E3d genome, which
instead had a fragment of 1.774 kb (Fig. 2, lane a). This is
consistent with the expected BamHI fragment sizes for
the wild-type and deletion mutants, thus confirming that
we had isolated an E3-deleted recombinant BAV3. Com-
parison of the growth characteristics of recombinant
virus with the wild-type BAV3 suggested no significant
differences in the plaque size or replication in, as E3-
deleted recombinant replicated with similar kinetics as
wild-type BAV3 (data not shown).
Construction of recombinant BAV3 expressing
glycoprotein gD
To determine the usefulness of E3-deleted (replica-
tion-competent) BAV3 recombinants as delivery vehi-
cles for live recombinant vaccine antigens, we con-
structed recombinant BAV3 expressing different forms
of BHV-1 glycoprotein gD (Tikoo et al., 1993). The
full-length and truncated form of gD genes (devoid of
any exogenous promoter) were inserted individually
into the E3 region of the BAV3.E3d genome in the same
transcriptional orientation of E3, using the ho-
mologous recombination machiner y of E. coli
(Degryse, 1996). The PacI-digested pFBAV302.gD or
pFBAV302.gDt plasmid DNA was transfected into
PFBR cells and produced cytopathic effects in 14 days.
The infected cell monolayers showing 50% cytopathic
effects were collected and freeze–thawed, and recom-
binant viruses were plaque purified and propagated in
MDBK cells. The recombinant BAV3s were named
BAV3.E3gD (full-length gD) and BAV3.E3gDt (truncated
gD). The viral DNA was extracted and analyzed by
agarose gel electrophoresis after digestion with differ-
ent restriction enzymes. Because the gD gene con-
tains a unique NdeI site (Tikoo et al., 1990), the re-
combinant viral DNA was cut with NdeI. As seen in
Fig. 2, compared with the BAV3.E3d (Fig. 2, lane e), the
BAV3.E3gD (Fig. 2, lane f) or BAV3.E3gDt (Fig. 2, lane g)
genomes contain an additional expected band of 4.6
kb, suggesting that recombinant BAV3.E3gD and
BAV3.gDt contained gD or gDt genes in the E3 region.
To differentiate between the gD and gDt gene, the
recombinant viral DNAs were digested with NheI be-
cause the gDt, but not the gD, gene contains a unique
NheI restriction enzyme site (Tikoo et al., 1993). As
expected, the 5.4-kb BAV3.E3gD DNA fragment (Fig. 2,
lane c) was replaced with a 5.0-kb fragment in
BAV3.E3gDt (Fig. 2, lane d). This suggested that re-
combinant BAV3.E3gD and BAV3.E3gDt contained gD
and gDt genes, respectively. A comparison of the
growth characteristics of these recombinants with
wild-type or E3-deleted BAV3 showed no significant
differences both in the kinetics of replication and in
the titer of virus produced (data not shown).
Analysis of expression of gD by BAV3.E3gD and
BAV3.E3gDt
To examine the product or products expressed by recom-
binant BAV3 containing the BHV-1 gD or gDt gene, MDBK
cells were infected with recombinant BAV3.E3gD,
BAV3.E3gDt, or BAV3.E3d and metabolically labeled
with [35S]methionine-cysteine for different time peri-
ods. For comparison with authentic gD, MDBK cells
were infected with BHV-1 and labeled similarly with
[35S]methionine-cysteine. The radiolabeled proteins
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FIG. 1. Construction of a plasmid containing E3-deleted BAV3 genomic DNA. The plasmid pFBAV302 was constructed from different genomic clones
as described in the text. The origin of the DNA sequences is as follows: plasmid DNA, thin line; BAV3 genomic DNA sequences, thick line. (Hollow
arrows) PCR primers: a, ACGCGTCGACTCCTCCTCA; b, TTGACAGCTAGCTTGTTG; c, CCAAGCTTGCATGCCTG; and d, GGCGATATCTCAGCTATAAC-
CGCTC. (The plasmid maps are not drawn to scale.)
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were immunoprecipitated with a pool of gD-specific
monoclonal antibodies (MAbs) (Hughes et al., 1988)
and analyzed by SDS–PAGE under reducing condi-
tions. The immunoprecipitation of recombinant BAV3.E3gD-
infected cells revealed a major band of ;71 kDa (Fig. 3A,
lanes b–d), which comigrated with the gD protein produced
in BHV-1-infected cells (Fig. 3A, lane a) suggesting that the
recombinant gD contained posttranslational modifications
similar to authentic gD. No similar band was observed in
uninfected cells (Fig. 3A, lane h) or cells infected with
recombinant BAV3.E3d (Fig. 3A, lanes e–g). Radioimmuno-
precipitation of recombinant BAV3.E3gDt-infected cell su-
pernatants revealed a major band of 61 kDa (Fig. 3B, lanes
b–d). No similar band was observed in the supernatants of
cells infected with BAV3.E3d (Fig. 3B, lanes e–g). Both
recombinant proteins were expressed throughout the infec-
tion of MDBK cells (Fig. 3).
To test the antigenicity of recombinant gD proteins,
radiolabeled proteins were immunoprecipitated from re-
combinant BAV3 infected cell lysate (BAV3.E3gD) or su-
pernatant (BAV3.E3gDt) with gD-specific MAbs (Hughes
et al., 1988) and analyzed by SDS–PAGE under reducing
conditions. As shown in Fig. 4, both gD (lanes 1–e) and
gDt (lanes f–j) proteins were recognized by MAbs di-
rected against discontinuous epitopes Ib (MAb 136;
lanes a and f), II (MAb 3E7; lanes b and g), IIIb (MAb 4C1;
lanes c and h) IIIC (MAb 2C8; lanes d and i), and IIId
(MAb 3C1; lanes e and j). These results suggests that the
antigenic structures of recombinant proteins gD and gDt
are similar to that of authentic gD produced in MDBK
cells (Tikoo et al., 1993).
To determine whether gD expression occurred in
the absence of DNA synthesis, we compared the
amount of gD produced in BAV3.E3gD-infected MDBK
FIG. 2. Restriction enzyme analysis of recombinant BAV3 genomes.
The DNAs were extracted from the BAV3- (lane b), BAV3.E3d- (lanes a
and e), BAV3.E3gD- (lanes c and f), and BAV3.gDt- (lanes d and g)
infected MDBK cells by Hirt’s method (Hirt, 1967) and digested with
BamHI (lanes a and b), NheI (lanes c and d), and NdeI (lanes e–g). The
1-kb-plus DNA ladder (M) from GIBCO BRL was used for sizing the viral
DNA fragments. The sizes of some marker bands are indicated by
arrows.
FIG. 3. Expression of gD proteins in MDBK cells infected with recombinant BAV3 viruses. (A) Proteins from lysates of radiolabelled MDBK cells
uninfected (lane h) or infected with BHV-1 (lane a), BAV3.E3d (lanes e–g), or BAV3.E3gD (lanes b–d) were immunoprecipitated with a pool of
gD-specific MAbs and analyzed by SDS–PAGE under reducing conditions. Proteins were labeled as 6–16 h (lanes a and h), 36–48 h (lanes b and e),
48–50 h (lanes c and f), and 60–62 h (lanes d and g) p.i. (B) Proteins from culture medium of radiolabeled MDBK cells infected with BHV-1 (lane a),
BAV3.E3d (lanes e–g), or BAV3.E3gDt (lanes b–d) were immunoprecipitated with a pool of gD-specific MAbs and analyzed by SDS–PAGE under
reducing conditions. Proteins were labeled as 6–16 h (lane a), 12–14 h (lanes b and e), 16–18 h (lanes c and f), and 22–26 h (lanes d and g) p.i.
Molecular size markers (MW) are given in kDa.
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cells in the presence (Fig. 5, lanes a and b) and
absence (Fig. 5, lanes c and d) of an inhibitor of DNA
synthesis, 1-b-D-arabinofuranosylcytosine (AraC). The
results suggest that gD expression was reduced in the
presence of AraC.
Antibody responses in animals
To determine the ability of BAV3 recombinants to in-
duce gD-specific immune responses, cotton rats were
inoculated twice intranasally, 3 weeks apart, with 107
PFU of BAV3.E3gD, BAV3.E3gDt, or BAV3.E3d recombi-
nants. Serum, lung washes, and nasal washes were
collected for the analysis of IgG and IgA antibodies,
whereas lungs were collected for analyzing the number
of IgA antibody-secreting cells (ASC). Both BAV3.E3gD
and BAV3.E3gDt induced gD-specific IgG antibody re-
sponse (Fig. 6B) in the serum and lung washes, which
was significantly higher (P , 0.05) than the response
induced in BAV3.E3d-immunized animals (control). How-
ever, gD-specific IgG response in the serum induced by
BAV3.E3gDt was higher than the response induced by
BAV3.E3gD (P , 0.05). No gD-specific IgG was detected
in the nasal washes (Fig. 6B).
FIG. 4. Antigenic analysis of recombinant gD and gDt proteins. Proteins from lysates (lanes a–e) and culture medium (lanes f–j) of radiolabeled
MDBK cells infected with BAV3.E3gD (lanes a–e) or BAV3.E3gDt (f–j) recombinant viruses were immunoprecipitated with MAb 136 (lanes a and f), MAb
3E7 (lanes b and g), MAb 4C1 (lanes c and h), MAb 2C8 (lanes d and i), and MAb 3C1 (lanes e and j) and analyzed by SDS–PAGE under reducing
conditions. Molecular size marker (MW) is given in kDa.
FIG. 5. Effect of AraC on gD expression in MDBK cells. Proteins from
lysates of MDBK cells infected with BAV3.E3gD (lanes a–d) in the
presence (lanes a and b) or absence (lanes c and d) of 100 ml/ml AraC
and radiolabeled for 2 h at 22 h (lanes a and c) or 34 h (lanes b and d)
p.i. were immunoprecipitated with a pool of gD MAbs and analyzed by
SDS–PAGE. Molecular size markers (MW) in kDa.
FIG. 6. Antibody responses in cotton rats. Glycoprotein gD- (A and B)
or BAV3- (C and D) specific IgA (A and C) or IgG (B and D) ELISA titers
in sera, lung washes (l.w), and nasal washes (n.w) 12 days after
secondary immunization with recombinant BAV3.E3d (stipled bar),
BAV3.E3gD (open bar), and BAV3.E3gDt (filled bar). Error bars represent
the standard error of the mean of four animals per group.
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Immunization with BAV3.E3gD and BAV3.E3gDt in-
duced significantly higher (P , 0.05) IgA antibody re-
sponses to gD in the serum and lung washes than
immunization with BAV3.E3d (Fig. 6A). However, there
was no significant difference in the IgA antibody re-
sponse between BAV3.E3gD- and the BAV3.E3gDt-
immunized groups. These recombinants also induced a
BAV3-specific IgG antibody response (Fig. 6D) in the
serum and lung washes and IgA antibody response (Fig.
6C) in serum, lung washes, and nasal washes, which
was not significant different among the groups.
Interestingly, nasal washes contained only IgA anti-
bodies specific for gD (Figs. 6A and 6B) or BAV3 (Figs. 6C
and 6D). In addition, IgA ASC specific for both gD and
BAV3 could be detected in the lung of immunized ani-
mals, the number of which increased significantly after
booster immunization (Table 1).
To measure the biological activity of the gD specific
serum antibody, anti-BHV-1 titers were determined. Im-
munization with BAV3.E3gDt induced a BHV-1 log2 titer of
4.3 6 0.5, which was significantly higher (P , 0.05) than
the titer of 3.0 6 0.6 and 0.8 6 0.3 induced by BAV3.E3gD
and BAV3.E3d, respectively.
DISCUSSION
Currently, recombinant human adenoviruses represent
one of the most efficient vector systems for delivery of
vaccine antigens to the mucosal surfaces. However, use
of human adenoviruses as a vaccine delivery system in
domestic animals is limited. Because nonhuman adeno-
viruses are species specific, the development of animal
specific adenovirus as a vaccine delivery system would
be a logical choice. In this report, we describe the de-
velopment of a replication-competent (E3-deleted) re-
combinant BAV3 for use in the delivery of vaccine anti-
gens to the mucosal surfaces of animals. In addition, we
constructed replication competent BAV3-expressing
BHV-1 gD or gDt glycoprotein and tested their ability to
induce mucosal and systemic immune responses in cot-
ton rats.
Initial attempts to isolate an E3-deleted BAV3 recom-
binant in different bovine cell lines, which support the
formation of infectious progeny after wild-type BAV3
DNA-mediated transfection, were unsuccessful. How-
ever, an E3 (partial)-deleted BAV3 recombinant-express-
ing luciferase gene was isolated when a BAV3 E1-
transformed MDBK cell line was used for transfection
(Mittal et al., 1995). This suggested that E1 region pro-
teins may be required for the isolation and propagation
of E3-deleted BAV3. However, recombinant BAV3-
expressing luciferase gene in E3 region replicated effi-
ciently in normal MDBK cells, suggesting that BAV3 E1
proteins are not required for the replication of E3-deleted
BAV3 (Mittal et al., 1995). Alternatively, the normal MDBK
cells may not be efficient for generating recombinant
BAV3. To develop a reliable and efficient method of
isolating replication-competent BAV3 recombinants with-
out using BAV3 E1-transformed MDBK cells, we first
used the homologous recombination machinery of E. coli
(Chartier et al., 1996; Degryse, 1996) to introduce a
1.245-kb deletion into the E3 region of full-length BAV3
genome cloned in a plasmid. Second, for isolating the
recombinant virus, we used PFBR cells instead of MDBK
cells for transfection of the modified BAV3 genome, ex-
cised from the plasmid.
It has been reported that up to 105% of the wild-type
genome can be packaged into the HAV5 virion without
causing any rearrangements or deletion of the foreign
genes in subsequent rounds of replication (Bett et al.,
1993). Recently, it was reported that the insertion capac-
ity of the ovine adenovirus (OAV) vector is 114% of the
wild-type genome (Xu et al., 1997). Because the size of
BAV3 genome is similar to that of the HAV5 genome, we
believe that the insertion capacity of BAV3 genome
should be similar to that of HAV5. Therefore, because the
BAV3.E3D vector has a 1.245-kb E3 deletion, the insertion
capacity of our present BAV3 vector should be ;3.0 kb.
Earlier, it was reported that recombinant BAV3.luc con-
taining a 0.696-kb deletion in the E3 region replicated
less efficiently than the wild type in cell culture (Mittal et
al., 1995). In contrast, the recombinant BAV3.E3d contain-
ing a 1.245-kb deletion in the E3 region replicated as
efficiently as the wild-type BAV3 in cell culture. This
difference may be due to the insertion of the luciferase
gene in recombinant BAV3.luc (Mittal et al., 1995), which
may affect the expression of genes downstream of the
E3 region (Mittal et al., 1995). However, the recombinant
BAV3.E3gD or BAV3.E3gDt also replicated as efficiently
as wild-type BAV3, suggesting that a foreign gene prod-
uct rather than the E3 insertion itself may be affecting the
replication of different recombinant BAV3 in cell culture.
To confirm the validity of the BAV3 vector system for
TABLE 1
Frequency of gD- and BAV3-Specific Antibody-Secreting Cells in
the Lungs of Cotton Rats Immunized Intranasally with Recombinant
Adenoviruses
Immunization
IgA
gD-specific
ASC/106 cells
BAV3-specific
ASC/106 cells
After first immunization
BAV3.E3gD 12 4
BAV3.E3gDt 4 4
After second immunization
BAV3.E3d 6 50
BAV3.E3gD 30 58
BAV3.E3gDt 22 40
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the expression of potential vaccine antigens, we con-
structed recombinant BAV3.E3gD- and BAV3.E3gDt-ex-
pressing BHV-1 gD or gDt glycoprotein, respectively. As
expected, gD expressed by BAV3.E3gD was of the ex-
pected molecular weight and comigrated with the au-
thentic gD expressed in BHV-1-infected cells. Similarly,
the gDt expressed by BAV3.E3gDt was of the expected
molecular weight (Tikoo et al., 1993). In addition, gD and
gDt expressed by BAV3 recombinants were recognized
by MAbs directed particularly against conformational
epitopes (Hughes et al., 1988). These results suggest
that recombinant gD and gDt had the posttranslational
modification and antigenic profiles indistinguishable
from those of the authentic gD synthesized after viral
infection (Hughes et al., 1988).
Foreign genes without any flanking regulatory se-
quences, inserted in the same transcriptional orientation
as E3, in the E3 region of human adenovirus are ex-
pressed efficiently, either from the upstream MLP or E3
promoter of the viral genome (Dronin et al., 1993; Morin
et al., 1987; Xu et al., 1995). Glycoprotein gD expression
was partially reduced in the presence of AraC, suggest-
ing that foreign gene expression was driven by both the
MLP and E3 promoter of BAV3. Similar results have been
reported for the luciferase gene expressed from the
partially deleted E3 region of BAV3 (Mittal et al., 1995). In
addition, it appears that gD-specific mRNAs may be
using BAV3 E3-specific poly(A)1 signals (Idamakanti,
1998). This suggestion is based on the following obser-
vations: (1) an E3 deletion vector still retains the E3-
specific polyA signal sequence, (2) the other probable
poly(A)1 signal sequence is ;3.3 kb from the E3-specific
poly(A)1 signal (Reddy et al., 1998), and (3) the gD genes
are not flanked by exogenous poly(A)1 signals.
Intranasal immunization of cotton rats with BAV3.E3gD
or BAV3.E3gDt induced gD-specific mucosal and sys-
temic immune responses. The gDt induced a higher IgG
antibody response than to gD. In contrast, intradermal
immunization of cotton rats with recombinant HAV5 in-
duced a lower immune response to gDt than to gD (Mittal
et al., 1996). A purified preparation of recombinant gDt
incorporated with an adjuvant when injected into mice
(Baca-Estrada et al., 1997) produced a secondary im-
mune response similar to that of authentic gD. This
strongly suggests that the route of immunization and
vaccine formulation may effect the ability of the immuno-
gen to induce an effective immune response and that
whether the immunogen is anchored in the membrane
(gD) or secreted as a soluble protein (gDt) may not in
itself influence the immunogenicity of the protein.
Surprisingly, gD and gDt elicited similar IgA but signif-
icantly different IgG responses in the serum. Mucosal
and systemic immune responses have been shown to be
elicited and regulated with a considerable degree of
independence (Alley and Mestecky, 1988; Conley and
Delacroix, 1987). Induction of an immune response in
one of these systems does not necessarily lead to a
response in the other. Thus it is possible that the two
different forms of gD are recognized differently in muco-
sal and systemic compartment.
Induction of mucosal immunity is thought to be crucial
in protecting the host from a respiratory or enteric infec-
tion. Moreover, secretory IgA has usually been found to
correlate with resistance to such infections (Murphy,
1994). Interestingly, intranasal immunization induced gD-
specific IgA antibody response, not only in the serum
and lung but also in nasal washes of cotton rats. A high
level of IgA and the presence of ASC in the lung suggest
that the antibody was produced locally.
In conclusion, we have described an efficient and
reliable system for the production of BAV3 recombinants.
In addition, we have shown that intranasal immunization
of cotton rats with replication competent recombinant
BAV3 induces vaccine antigen-specific mucosal and sys-
temic immune responses.
MATERIALS AND METHODS
Cells and viruses
MDBK cells and PFBR cells were grown in Eagle’s
minimum essential medium (MEM) supplemented with
5% fetal bovine serum (FBS). The wild-type (WBR-1 strain)
and recombinant BAV3s were propagated in MDBK cells
as described previously (Mittal et al., 1995). The P8-2
strain of BHV-1 was propagated and quantified as de-
scribed earlier (Rouse and Babiuk, 1974).
Animals
An inbred colony of cotton rats (Sigmodon hispidus)
maintained at the Veterinary Infectious Disease Organi-
zation Saskatoon was the source of animals for this
study.
Construction of recombinant plasmids
Construction of plasmid pFBAV302. A T4 polymerase-
treated 587-bp fragment isolated by PCR amplification
[using oligonucleotides (1) ACGCGTCGACTCCTCCTCA
and (2) TTGACAGCTAGCTTGTTG; and plasmid pSM14
(Mittal et al., 1995) as a template] was digested with
SacII and ligated to Eco47III–SacII-digested plasmid
pSL301 creating plasmid pE3A. A 164-bp fragment iso-
lated by PCR amplification [using oligonucleotides (1)
CCAAGCTTGCATGCCTG and (2) GGCGATATCTCAGCT-
ATAACCGCTC and plasmid pSM14 (Mittal et al., 1995)]
was digested with SphI–EcoRV and ligated to 531-bp
EcoRV–HindIII fragment of pE3A and SphI–HindIII-
digested plasmid pSL301 creating plasmid pE3B. The
614-bp SphI–SacII fragment was isolated from plasmid
pE3B and ligated to SphI–SacII-digested pSM14 to cre-
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ate plasmid pE3C. The plasmid pE3C was digested with
EcoRV and ligated to SrfI linker (TTGCCCGGGCTT) cre-
ating plasmid pE3C1. A 1.755-kb BamHI fragment of
pE3C1 was isolated and ligated to BamHI-digested
pSM17 (Mittal et al., 1995) creating plasmid pE3D. Finally,
a 8783-bp KpnI–XbaI fragment of plasmid pE3D was
isolated and ligated to KpnI–XbaI-digested plasmid
pTG5435 (which contains full-length BAV3 genomic DNA)
to create plasmid pE3E. The plasmid pE3E contained
end fragments of the BAV3 genome (0–19.7 m.u. and
76.6–100 m. u.) with a 1.245-kb deletion in the E3 region
and a unique KpnI site.
The plasmid (pFBAV302) containing the BAV3 genome
with a 1.245-kb deletion in the E3 region was generated
by homologous DNA recombination between KpnI-di-
gested pE3E and deproteinized BAV3 genomic DNA in E.
coli BJ5183 (Degryse et al., 1996).
Construction of plasmid pFBAV302.gD and pFBAV302.gDt.
The transfer plasmid for generation of recombinant BAV3-
expressing foreign genes in the E3 region was constructed
by ligating a 8783-bp KpnI–XbaI fragment of pFBAV302 to a
KpnI–XbaI-digested plasmid pGEM3zf(2), creating plasmid
pBAV300. A 1.3-kb BglII fragment of a plasmid pRSV1.3
(Tikoo et al., 1993) containing a BHV-1 full-length gD gene
was treated with T4 DNA polymerase and ligated to SrfI-
digested pBAV300, creating plasmid pBAV300.gD. Similarly,
a 1.3-kb Bg1II fragment of plasmid pRSV1.3XN (Tikoo et al.,
1993) containing a BHV-1 truncated gD gene was treated
with T4 DNA polymerase and ligated to SrfI-digested
pBAV300, creating plasmid pBAV300.gDt.
The recombinant BAV3 genome containing a gene
encoding full-length (pFABV302.gD) or truncated
(pFBAV302.gDt) gD protein was generated by homol-
ogous DNA recombination in E. coli BJ5183 between
SrfI linearized pFBAV302 and a 10-kb KpnI–XbaI
fragment of pBAV300.gD or between SrfI linearized
pFBAV302 and a 10-kb KpnI–XbaI fragment of
pBAV300gDt, respectively.
Construction of recombinant BAV3
PFBR cell monolayers in 60-mm dishes were trans-
fected with 10 mg of PacI-digested pFBAV302,
pFBAV302.gD, or pFDBAV302.gDt recombinant plas-
mid DNAs using the Ca21-phosphate method (Graham
and van der Eb, 1973). After 15–20 days of incubation
at 37°C, the transfected cells showing 50% cytopathic
effects were collected and freeze-thawed two times,
and the recombinant virus was plaque purified on
MDBK cells (Mittal et al., 1995).
Radiolabeling and immunoprecipitation on proteins
About 70–80% confluent MDBK cell monolayers in 28-
cm2 wells were infected with 10 pfu of recombinant or
wild-type BAV3 per cell. After virus absorption for 60 min,
the cells were incubated in MEM containing 5% FBS. At
different times p.i., the cells were incubated in methio-
nine–cysteine-free Dulbucco’s modified Eagle’s medium
(DMEM) for 60 min before labeling with [35S]methionine-
cysteine (100 mCi/well). After 2 or 12 h of labeling, the
cells or medium was harvested. Proteins were immuno-
precipitated from the medium or the cells lysed with
modified radioimmunoprecipitation (RIPA) buffer and an-
alyzed by SDS–PAGE as described previously (Tikoo et
al., 1993).
Animal inoculations
A total of 25 cotton rats (4 to 6 weeks old) of either sex
were divided into three groups (nine animals/group). After
inducing anesthesia in the animals with halothane, animals
were inoculated twice at day 1 and day 21 by the intranasal
route with 100 ml of inoculum containing 107 pfu of individ-
ual recombinant virus. Blood samples were collected at
days 0, 21, and 28 after the primary inoculation to examine
the development of BHV-1 gD-specific and BAV3-specific
antibodies by enzyme-linked immunosorbent assays
(ELISA) and virus neutralization (VN) assays. Four animals
in each group were killed at 21 and 28 days after the
primary inoculation by an overdose of halothane. The lung
and nasal secretions were collected separately to monitor
the development of BHV-1 gD-specific and BAV3-specific
mucosal IgG and IgA antibody responses by ELISA (Papp
et al., 1997). In addition, lungs were collected to determine
the frequency of BHV-1 gD- and BAV3-specific IgA antibody
secreting cells by enzyme-linked immunospot (ELISPOT)
(Papp et al., 1997).
Preparation of lymphocytes from the lungs
Aseptically removed lung tissue was cut into small
pieces and incubated in complete medium: MEM sup-
plemented with 10% FBS, 2 mM L-arginine, 1 mM sodium
pyruvate, 100 mM nonessential amino acids, and 10 mM
HEPES buffer plus 100 U/ml penicillin G, 100 mg/ml
streptomycin solution, 150 U/ml collagenase A, and 50
U/ml Dnase I for 1 h and then pushed through a plastic
mesh. The lung cell suspension was centrifuged through
a discontinuous Percoll gradient and washed with MEM.
The cells were resuspended in complete medium and
incubated for 1 h in a flask to attach adherent cells. The
nonadherent cell population was then resuspended and
used in the antigen-specific ELISPOT assay as de-
scribed earlier (Papp et al., 1997).
ELISA
Antibodies specific for BHV-1 and BAV3 in sera in lung
and nasal secretions were determined by ELISA as de-
scribed earlier (Papp et al., 1997). Briefly, 96-well Immu-
nol-2 microtiter plates were coated with either purified
truncated gD (0.01 mg/well) or BAV3 (0.5 mg/well) and
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incubated with different dilutions of each sample. Anti-
gen-specific IgG was detected using biotinylated rabbit
anti-rat IgG. Antigen-specific IgA was measured by rab-
bit anti-rat IgA and horseradish peroxidase-conjugated
goat anti-rabbit IgG.
Virus neutralization
Two-fold serial dilutions of heat-inactivated serum
samples were incubated with 100 pfu and BHV-1 for
1 h at 37°C. The virus-sample mixture was then plated
onto confluent MDBK cells in 12-well tissue culture
plates and incubated for 2 days. Titers were ex-
pressed as reciprocals of the highest antibody dilution
that caused 50% reduction in the number of plaques
relative to the control.
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